Posted inBiotechnology
Posted inBiotechnology
Former Seagen CEO’s biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic
Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in…






















